Human TREM2 Protein, His Tag
分子別名(Synonym)
Triggering receptor expressed on myeloid cells 2,TREM2,TREM-2
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human TREM2, His, Tag (TR2-H52H5) is expressed from human 293 cells (HEK293). It contains AA His 19 - Ser 174 (Accession # Q9NZC2-1).
Predicted N-terminus: His 19
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 19.3 kDa. The protein migrates as 28-35 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
TREM2是免疫球蛋白超家族的細(xì)胞表面受體。TREM2存在于各種組織巨噬細(xì)胞中,如中樞神經(jīng)系統(tǒng)小膠質(zhì)細(xì)胞、骨破骨細(xì)胞、肺泡、腹膜和腸巨噬細(xì)胞。TREM2也存在于培養(yǎng)的骨髓來源的巨噬細(xì)胞和單核細(xì)胞來源的樹突狀細(xì)胞上。一些研究已經(jīng)確定了TREM2的一種罕見變體,這是阿爾茨海默?。?/span>AD)的危險(xiǎn)因素,阿爾茨海默病是最常見的遲發(fā)性癡呆癥。TREM2的細(xì)胞外區(qū)域包含一個(gè)免疫球蛋白超家族結(jié)構(gòu)域,并結(jié)合多陰離子配體,如細(xì)菌脂多糖(LPS)和磷脂8。配體結(jié)合后,TREM2通過銜接子DAP12(也稱為TYRO蛋白酪氨酸激酶結(jié)合蛋白(TYROBP))傳遞細(xì)胞內(nèi)信號(hào),DAP12與TREM2的跨膜區(qū)相關(guān),并通過其細(xì)胞質(zhì)免疫受體酪氨酸基激活基序(ITAM)招募蛋白酪氨酸激酶SYK。TREM2是小鼠模型和人類腫瘤中腫瘤浸潤巨噬細(xì)胞的促致瘤標(biāo)志物,可以靶向抑制腫瘤生長,提高檢查點(diǎn)阻斷治療的療效,同時(shí)重塑腫瘤浸潤巨噬細(xì)胞景觀。
關(guān)鍵字: TREM2;TREM2蛋白;TREM2重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。